Subscribe
-
Our fight against Covid-19CanSinoBIO is dedicated to establishing mass immune protection to the global population in a timely manner by working around the clock to develop the single-shot COVID-19 vaccine Convidecia. -
Our main focus is innovative and high-quality vaccine for human useOur goal is to promote the development and commercialization of our vaccine products and contribute to improving the quality of public health worldwide. -
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine in ChinaCanSino Biologics Inc. announced that the National Medical Products Administration of China granted conditional marketing authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™), making it the first of its kind authorized in China.
Development And Product
At CanSinoBIO, our main research and development focus is vaccines.
Areas Of Focus
We apply our expertise across a range targets from antigen discovery, antigen overexpression, purification and formulation to proof-of-concept pre-clinical evaluation, production process development and assay development.
Pipeline
We have an impressive array of vaccine candidates currently undergoing pre-clinical studies including recombinant protein-based pneumococcal vaccines, adenovirus-based recombinant TB vaccines, and polyvalent conjugate vaccines.
Technology Platform
Our team works with world’s most advanced equipment and lab resources for microbiology, molecular cell biology, immunology and biochemistry. We also maintain top- notch animal research facilities.
Investors
We apply our expertise across a range targets from antigen discovery, antigen overexpression,
purification and formulation to proof-of-concept pre-clinical evaluation,
production process development and assay development.
purification and formulation to proof-of-concept pre-clinical evaluation,
production process development and assay development.
Information disclosure
Stock information
Corporate governance
Calendar
-
09/102024
